Oculis Holding AG Ordinary shares (NASDAQ:OCS) — Market Cap & Net Worth
Market Cap & Net Worth: Oculis Holding AG Ordinary shares (OCS)
Oculis Holding AG Ordinary shares (NASDAQ:OCS) has a market capitalization of $574.63 Million ($574.63 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11588 globally and #2971 in its home market, demonstrating a -18.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oculis Holding AG Ordinary shares's stock price $9.91 by its total outstanding shares 57984438 (57.98 Million). Also see OCS total assets for a full breakdown of the balance sheet.
Oculis Holding AG Ordinary shares Market Cap History: 2021 to 2026
Oculis Holding AG Ordinary shares's market capitalization history from 2021 to 2026. Data shows growth from $561.87 Million to $574.63 Million (0.40% CAGR). Also see Oculis Holding AG Ordinary shares (OCS) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Oculis Holding AG Ordinary shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #320 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1171 of 3165 |
Weight: Oculis Holding AG Ordinary shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oculis Holding AG Ordinary shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oculis Holding AG Ordinary shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check OCS share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1436.93x
Oculis Holding AG Ordinary shares's market cap is 1436.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $561.87 Million | $960.00K | -$18.55 Million | 585.28x | N/A |
| 2022 | $585.64 Million | $912.00K | -$38.70 Million | 642.15x | N/A |
| 2023 | $651.17 Million | $883.00K | -$88.80 Million | 737.45x | N/A |
| 2024 | $985.74 Million | $686.00K | -$85.78 Million | 1436.93x | N/A |
Competitor Companies of OCS by Market Capitalization
Companies near Oculis Holding AG Ordinary shares in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Oculis Holding AG Ordinary shares to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Oculis Holding AG Ordinary shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Oculis Holding AG Ordinary shares Historical Marketcap From 2021 to 2026
Between 2021 and today, Oculis Holding AG Ordinary shares's market cap moved from $561.87 Million to $ 574.63 Million, with a yearly change of 0.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $574.63 Million | -50.38% |
| 2025 | $1.16 Billion | +17.47% |
| 2024 | $985.74 Million | +51.38% |
| 2023 | $651.17 Million | +11.19% |
| 2022 | $585.64 Million | +4.23% |
| 2021 | $561.87 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Oculis Holding AG Ordinary shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $574.63 Million USD |
| MoneyControl | $574.63 Million USD |
| MarketWatch | $574.63 Million USD |
| marketcap.company | $574.63 Million USD |
| Reuters | $574.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more